Core Viewpoint - TianKang (301263) announced that its wholly-owned subsidiary, Shandong Huabo Kaisheng Biotechnology Co., Ltd., received the acceptance notice for the registration and listing application of montmorillonite suspension from the National Medical Products Administration [1] Group 1 - The acceptance number for the drug registration is CYHS2501498, with a specification of 10g:3g [1] - Montmorillonite suspension is primarily used for treating acute and chronic diarrhea in adults and children, offering unique advantages over montmorillonite powder, which may allow it to capture a larger market share in the future [1] - Currently, only three companies in China have obtained the drug registration certificate for montmorillonite suspension [1]
泰恩康：蒙脱石混悬液获药品注册受理通知书